TScan Therapeutics (TCRX) Operating Leases (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Operating Leases data on file, last reported at $52.4 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 12.42% year-over-year to $52.4 million in Q1 2026; TTM through Mar 2026 was $52.4 million, a 12.42% decrease from a year earlier, with the FY2025 full-year figure at $54.4 million, down 10.38% from the prior year.
• Operating Leases for Q1 2026 stood at $52.4 million, down from $54.4 million in the prior quarter.
• Over the last five years, Operating Leases for TCRX reached as high as $60.7 million in Q4 2024 and fell as low as $3.0 million in Q3 2022.
• Historically, Operating Leases has averaged $46.7 million across 5 years, with a median of $54.4 million in 2025.
• Across the five-year window, Operating Leases tumbled 36.74% in 2022 and surged 1637.45% in 2023, its largest moves.
• Year by year, Operating Leases stood at $53.0 million in 2022, then grew by 11.56% to $59.1 million in 2023, then increased by 2.7% to $60.7 million in 2024, then declined by 10.38% to $54.4 million in 2025, then dropped by 3.66% to $52.4 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $52.4 million in Q1 2026, $54.4 million in Q4 2025, and $56.3 million in Q3 2025.